Periodic Reporting for period 1 - SENSITIVITYMARKERS (Clinical validation of prognostic biomarkers of chemotherapy response in liquid biopsies)

NTRC is a precision medicine company dedicated to the development of new anti-cancer drugs that target activated or mutated cancer genes. NTRC’s activities are focused around internal programmes and services to companies active in oncology. With support of the SME Instrument...